» Articles » PMID: 36103516

Cold Shock Domain-containing Protein E1 is a Posttranscriptional Regulator of the LDL Receptor

Abstract

The low-density lipoprotein receptor (LDLR) controls cellular delivery of cholesterol and clears LDL from the bloodstream, protecting against atherosclerotic heart disease, the leading cause of death in the United States. We therefore sought to identify regulators of the LDLR beyond the targets of current therapies and known causes of familial hypercholesterolemia. We found that cold shock domain-containing protein E1 (CSDE1) enhanced hepatic messenger RNA (mRNA) decay via its 3' untranslated region and regulated atherogenic lipoproteins in vivo. Using parallel phenotypic genome-wide CRISPR interference screens in a tissue culture model, we identified 40 specific regulators of the LDLR that were not previously identified by observational human genetic studies. Among these, we demonstrated that, in HepG2 cells, CSDE1 regulated the LDLR at least as strongly as statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. In addition, we showed that hepatic gene silencing of treated diet-induced dyslipidemia in mice to a similar degree as silencing. These results suggest the therapeutic potential of targeting CSDE1 to manipulate the posttranscriptional regulation of the mRNA for the prevention of cardiovascular disease. Our approach of modeling a clinically relevant phenotype in a forward genetic screen, followed by mechanistic pharmacologic dissection and in vivo validation, may serve as a generalizable template for the identification of therapeutic targets in other human disease states.

Citing Articles

CSDE1: a versatile regulator of gene expression in cancer.

Ciocia A, Mestre-Farras N, Vicent-Nacht I, Guitart T, Gebauer F NAR Cancer. 2024; 6(2):zcae014.

PMID: 38600987 PMC: 11005786. DOI: 10.1093/narcan/zcae014.


Post-translational regulation of the low-density lipoprotein receptor provides new targets for cholesterol regulation.

Aldworth H, Hooper N Biochem Soc Trans. 2024; 52(1):431-440.

PMID: 38329179 PMC: 10903450. DOI: 10.1042/BST20230918.


CRISPR screening in cardiovascular research.

Shan H, Fei T Front Cell Dev Biol. 2023; 11:1175849.

PMID: 37123412 PMC: 10130668. DOI: 10.3389/fcell.2023.1175849.


Rapid Multiplexed Flow Cytometric Validation of CRISPRi sgRNAs in Tissue Culture.

Chorba J, Xia V, Smith G, Padmanabhan A Bio Protoc. 2023; 13(2).

PMID: 36789164 PMC: 9901452. DOI: 10.21769/BioProtoc.4591.


Heparin Does Not Regulate Circulating Human PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) in a General Population-Brief Report.

Xia V, Ong C, Zier L, MacGregor J, Wu A, Chorba J Arterioscler Thromb Vasc Biol. 2022; 43(2):352-358.

PMID: 36475702 PMC: 10038152. DOI: 10.1161/ATVBAHA.122.318556.

References
1.
Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

2.
Bjornsson E, Gunnarsdottir K, Halldorsson G, Sigurdsson A, Arnadottir G, Jonsson H . Lifelong Reduction in LDL (Low-Density Lipoprotein) Cholesterol due to a Gain-of-Function Mutation in . Circ Genom Precis Med. 2020; 14(1):e003029. DOI: 10.1161/CIRCGEN.120.003029. View

3.
Adamson B, Norman T, Jost M, Cho M, Nunez J, Chen Y . A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response. Cell. 2016; 167(7):1867-1882.e21. PMC: 5315571. DOI: 10.1016/j.cell.2016.11.048. View

4.
Mazein A, Watterson S, Hsieh W, Griffiths W, Ghazal P . A comprehensive machine-readable view of the mammalian cholesterol biosynthesis pathway. Biochem Pharmacol. 2013; 86(1):56-66. PMC: 3912678. DOI: 10.1016/j.bcp.2013.03.021. View

5.
Loregger A, Nelson J, Zelcer N . Assaying Low-Density-Lipoprotein (LDL) Uptake into Cells. Methods Mol Biol. 2017; 1583:53-63. DOI: 10.1007/978-1-4939-6875-6_5. View